Moderate riskFDA DrugClass II

Adbry (tralokinumab-ldrm) injection recalled for particulate contamination

LEO Pharma is recalling specific lots of Adbry, a prescription injection used to treat atopic dermatitis, because one unit was found to contain wool fiber particles. This contamination raises concerns about sterility and safety. No injuries have been reported so far.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have Adbry from lot 003E24C (expires 04/30/2027) or lot 003E24A (expires 04/30/2027)
  2. Do not use the medication if it matches these lot numbers
  3. Contact your pharmacy or prescriber for a replacement or alternative treatment
  4. Call LEO Pharma or the FDA with questions about your specific lot

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA,
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Units affected
11,407 units
Illnesses reported
None reported
Manufactured in
7 Giralda Farms, N/A, Madison, NJ, United States
Classification
Class II
Recall number
D-0339-2026

In the FDA's words

Description
Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA, Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber. Lot: a) 003E24C, Exp 04/30/2027; b) 003E24A, Exp 04/30/2027. Distribution: Nationwide in the USA Affected quantity: 11,407 units
Hazard
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Related topics

ParticulateSterilityDrugsSold nationwideMore from FDA Drug